


**Novel Coronavirus:
nCoV-2019
COVID-19
SARS-CoV-2**

Zhu et al. N Engl J Med 2020;382:727-33.

Guido van Marle, MSc, PhD
Dept. Microbiology Immunology & Infectious Disease
Cumming School of Medicine
University of Calgary

Order: Nidovirales




ICTV

https://talk.ictvonline.org/ictv-reports/ictv_9th_report/positive-sense-rna-viruses-2011/w/posrna_viruses/223/coronaviridae-figures
https://talk.ictvonline.org/ictv-reports/ictv_9th_report/positive-sense-rna-viruses-2011/w/posrna_viruses/219/nidovirales

Coronavirus

Coronaviruses

- Order: Nidovirales
- Family: Coronaviridae
 - Subfamily: Orthocoronavirinae
- Positive Strand RNA virus
- Genome size up to ~26-32 kb
- Host ranges mammals and avians
 - Important veterinary pathogens
 - IBV, TGEV, PEDV
 - Humans
 - Common cold hCoV 229E, NL63, OC43
 - Middle Eastern Respiratory Syndrome (MERS) CoV
 - Severe Acute Respiratory Syndrome (SARS) CoV
 - SARS-CoV-2 (COVID-19)




ICTV 9th Report (2011)

https://talk.ictvonline.org/ictv-reports/ictv_9th_report/positive-sense-rna-viruses-2011/w/posrna_viruses/223/coronaviridae-figures





Emergence of Coronaviruses

Virus	Species	Emergence
HCoV-NL63	Human	500-800 years
HCoV-229E	Human	200-300 years
HCoV-OC43	Human	~120 years
PEDV	Porcine	~25 years
rBCoV	Bovine	~25 years
SARS-CoV	Human	~16 years
MERS-CoV	Human	~7 years
SADS-CoV (HKU2)	Porcine	~2 years
SARS-CoV-2	Human	Present

Fu et al. 2018 Infect Gen Evol; Peiris et al. Lancet 2003; Huynh et al. J Virol 2012; Zaki et al N Engl J Med 2013; Mole Nature 2013; Zhou et al Nature 2018




<https://special.croi.capitalreach.com/>



Therapeutic Approaches & Vaccines?

Coronavirus Life cycle



Receptors for Cell Entry

HCoV-229E	APN
HCoV-NL63	ACE2
TGEV	APN
PEDV	APN
FIPV	APN
CCoV	APN
MHV	mCEACAM
SARS-CoV	ACE2
MERS-CoV	DPP4

Fehr & Perlman
Methods Mol Biol.
(2015) 1282: 1–23.

Fung et al.
Front Microbiol
(2014) 5:296

Potential Vaccines:

- Targets structural proteins (S, M, N)
- Humoral and Cellular Immune are protective

But:

- Antibody Dependent Enhancement of infection (ADE)?
- Other Immune Pathologies?
- Longevity of Response?
- Immune escape?

Potential Antivirals:

- Block virus binding or entering cells
- Protease inhibitors against viral proteases
 - Papain like proteases
 - Chymotrypsin like proteases
- Target other Non Structural Proteins (nsp).
 - Replicase (Remdesivir)
- Target Viral Accessory Proteins
- Target Interferon Responses
- Other cellular processes & antiviral responses

